Literature DB >> 19067215

Mice transgenic with SV40-late-promoter-driven Polyomavirus Middle T oncogene exclusively develop hemangiomas.

Qin Xu1, Wantao Chen, Zhugang Wang, Jiawei Zheng, Zhiyuan Zhang.   

Abstract

In order to develop a model system of infantile hemangioma, transgenic mice were developed carrying the Polyomavirus Middle T (PyMT) gene driven by the SV40 late promoter. From the 520 fertilized eggs surviving microinjection, there were 25 live births. Three of these showed the hemangioma phenotype and carried and expressed the PyMT gene; the remaining descendants were normal. The tumors showed abnormal vascular proliferation with cavernous hemangioma-like structures in the skin surface, tongue, ear mucosa and gastric mucosal tissue in the transgenic mice with hemangioma phenotype. Immunohistochemical staining for Ki-67 was negative, showing the tumors were hemangiomas rather than angiosarcomas. None of the PyMT transgenic mice survived beyond 4 weeks. Previously reported PyMT transgenic mice under the control of various promoters induce many tumor types including hemangiomas. PyMT driven by the SV40 late promoter is an improved model system because it only induces hemangiomas. However, it is limited by the post-natal lethality. Thus, conditional variants of this model system would be desirable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067215     DOI: 10.1007/s11248-008-9232-1

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  22 in total

1.  Human endothelial cells expressing polyoma middle T induce tumors.

Authors:  L Primo; C Roca; C Ferrandi; L Lanfrancone; F Bussolino
Journal:  Oncogene       Date:  2000-07-27       Impact factor: 9.867

2.  Telomere length in small-for-gestational-age babies.

Authors:  A Akkad; R Hastings; J C Konje; S C Bell; H Thurston; B Williams
Journal:  BJOG       Date:  2006-03       Impact factor: 6.531

3.  Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene.

Authors:  V L Bautch; S Toda; J A Hassell; D Hanahan
Journal:  Cell       Date:  1987-11-20       Impact factor: 41.582

4.  Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene.

Authors:  R L Williams; S A Courtneidge; E F Wagner
Journal:  Cell       Date:  1988-01-15       Impact factor: 41.582

5.  A polyomavirus enhancer mutant confers ubiquitous high transcriptional efficiency to the SV40 late promoter.

Authors:  G M Fimia; R Ferreira; C Passananti; P Amati
Journal:  Biochem Biophys Res Commun       Date:  1995-02-06       Impact factor: 3.575

6.  Differential sensitivity of mouse epithelial tissues to the polyomavirus middle T oncogene.

Authors:  Grace Cecena; Fang Wen; Robert D Cardiff; Robert G Oshima
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

7.  Genetically engineered models have advantages over xenografts for preclinical studies.

Authors:  Oren J Becher; Eric C Holland
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Construction and functional characterization of polyomavirus genomes that separately encode the three early proteins.

Authors:  Z Y Zhu; G M Veldman; A Cowie; A Carr; B Schaffhausen; R Kamen
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Isolation and characterization of an established endothelial cell line from transgenic mouse hemangiomas.

Authors:  N A Dubois; L C Kolpack; R Wang; R G Azizkhan; V L Bautch
Journal:  Exp Cell Res       Date:  1991-10       Impact factor: 3.905

10.  Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs.

Authors:  R L Brinster; H Y Chen; M Trumbauer; A W Senear; R Warren; R D Palmiter
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

View more
  1 in total

1.  Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.

Authors:  Furong Xie; Xin Bao; Jingshuang Yu; Wantao Chen; Lizhen Wang; Zhiyuan Zhang; Qin Xu
Journal:  Oncotarget       Date:  2015-09-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.